| Recruiting | A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and D Amyloidosis | Phase 3 | 2026-01-08 |
| Recruiting | A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer. Non-Small Cell Lung Carcinoma (NSCLC) | Phase 3 | 2025-12-30 |
| Recruiting | A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexame Multiple Myeloma (MM) | Phase 3 | 2025-12-29 |
| Not Yet Recruiting | Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa Hidradenitis Suppurativa (HS) | Phase 2 | 2025-11-18 |
| Not Yet Recruiting | Phase I/II Study of SCTB39G in Advanced Solid Tumours Advanced Malignant Solid Tumor | Phase 1 / Phase 2 | 2025-07-28 |
| Recruiting | Phase I/II Study of SCTB39-1 in Advanced Solid Tumours Advanced Malignant Solid Tumor | Phase 1 / Phase 2 | 2025-06-23 |
| Not Yet Recruiting | A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease. TED | Phase 1 / Phase 2 | 2025-02-19 |
| Not Yet Recruiting | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine Herpes Zoster | Phase 1 / Phase 2 | 2025-02-15 |
| Recruiting | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Respiratory Syncytial Virus | Phase 1 / Phase 2 | 2025-02-06 |
| Recruiting | A Study of SCTB35 in Patients with Systemic Lupus Erythematosus System Lupus Erythematosus | Phase 1 / Phase 2 | 2025-02-01 |
| Not Yet Recruiting | A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases IgA Nephropathy | Phase 1 / Phase 2 | 2025-01-01 |
| Recruiting | Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients Wi nAMD | Phase 1 / Phase 2 | 2024-11-26 |
| Recruiting | Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced M Advanced Malignant Solid Tumours | Phase 1 / Phase 2 | 2024-10-10 |
| Not Yet Recruiting | Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis Axial Spondyloarthritis | Phase 2 | 2024-07-01 |
| Not Yet Recruiting | Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced M Advanced Malignant Solid Tumours | Phase 1 / Phase 2 | 2024-04-30 |
| Recruiting | Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients. Haemophilia A | Phase 3 | 2024-04-26 |
| Not Yet Recruiting | A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma, B-cell | Phase 1 | 2024-04-01 |
| Recruiting | A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies Relapsed or Refractory Hematologic Malignancies | Phase 1 | 2024-02-28 |
| Active Not Recruiting | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years HPV InfectioN, HPV-Related Carcinoma | Phase 3 | 2023-08-13 |
| Unknown | A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccine COVID-19, SARS-CoV-2 Infection | Phase 2 | 2023-08-10 |
| Unknown | Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers Autoimmune Disease | Phase 1 | 2023-06-01 |
| Unknown | Study on the Antibody Level Against SARS-CoV-2 （COVID-19）in Dazhu County in 2023 COVID-19 | — | 2023-02-21 |
| Unknown | This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With R Wet Age-related Macular Degeneration | Phase 3 | 2023-02-14 |
| Unknown | A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People COVID-19 SARS-CoV-2 Infection | Phase 3 | 2023-01-25 |
| Completed | A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-1 COVID-19 Pandemic | Phase 2 | 2023-01-05 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years COVID-19, SARS-CoV-2 Infection | Phase 3 | 2022-12-26 |
| Unknown | A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Popul COVID-19, SARS-CoV-2 Infection | Phase 2 | 2022-10-15 |
| Unknown | A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged SARS-CoV-2 Infection, COVID-19 | Phase 2 | 2022-07-01 |
| Unknown | A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose COVID-19, SARS-CoV-2 Infection | Phase 2 | 2022-07-01 |
| Unknown | SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell C Head and Neck Squamous Carcinoma | Phase 1 | 2022-06-15 |
| Unknown | A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population A COVID-19, SARS-CoV-2 Infection | Phase 3 | 2022-05-30 |
| Withdrawn | A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated Wit COVID-19, SARS-CoV2 Infection | Phase 2 | 2022-04-25 |
| Unknown | A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged COVID-19, SARS-CoV-2 Infection | Phase 2 | 2022-04-01 |
| Withdrawn | A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vac COVID-19, SARS-CoV-2 Infection | Phase 2 | 2022-04-01 |
| Unknown | A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Pr COVID-19, Sars-CoV-2 Infection | Phase 2 | 2022-03-20 |
| Unknown | A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years an COVID-19, SARS-CoV-2 Infection | Phase 2 | 2022-03-20 |
| Withdrawn | A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19 COVID-19 | Phase 1 / Phase 2 | 2022-01-15 |
| Unknown | The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inact COVID-19, SARS-CoV-2 Infection | Phase 1 / Phase 2 | 2021-12-22 |
| Unknown | The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19, SARS-CoV-2 Infection | Phase 1 / Phase 2 | 2021-12-22 |
| Completed | The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults COVID-19 | Phase 1 / Phase 2 | 2021-12-01 |
| Unknown | A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years Interventional, Prevention, Randomized | Phase 2 | 2021-10-19 |
| Unknown | A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years HPV Infection Vaccine Safety SCT1000 | Phase 1 | 2021-07-02 |
| Not Yet Recruiting | To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19 COVID-19, SARS-CoV-2 | Phase 2 / Phase 3 | 2021-03-28 |
| Terminated | The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19 Covid19 | Phase 2 / Phase 3 | 2021-03-27 |
| Unknown | The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care Covid19 | Phase 2 / Phase 3 | 2021-02-25 |
| Unknown | SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma Hepatocellular Carcinoma | Phase 2 / Phase 3 | 2020-11-11 |
| Unknown | The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD) Wet Age-related Macular Degeneration | Phase 1 / Phase 2 | 2020-11-06 |
| Completed | Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chines Coronavirus Disease 2019(COVID-19) | Phase 1 | 2020-07-24 |
| Unknown | Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC Esophageal Squamous Cell Carcinoma, Colorectal Cancer | Phase 1 | 2020-03-01 |
| Unknown | SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma Head and Neck Squamous Cell Carcinoma | Phase 3 | 2019-12-31 |
| Unknown | Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Sever Hemophilia A | Phase 3 | 2019-12-20 |
| Unknown | Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma Head and Neck Squamous Cell Carcinoma | Phase 2 | 2019-10-31 |
| Terminated | SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer Squamous-cell Non-Small-cell Lung Cancer | Phase 3 | 2019-10-22 |
| Unknown | The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Psoriasis | Phase 3 | 2019-09-05 |
| Unknown | Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients. Hemophilia A | Phase 4 | 2019-07-26 |
| Completed | Pharmacokinetics and Safety in Healthy Volunteers Healthy | Phase 1 | 2019-05-29 |
| Unknown | SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma Head and Neck Squamous Cell Carcinoma | Phase 2 | 2019-05-21 |
| Unknown | Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer Advanced Squamous Non-small Cell Lung Cancer | Phase 1 | 2019-03-01 |
| Unknown | To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer Non-squamous Cell Non-small Cell Lung Cancer | Phase 3 | 2019-02-01 |
| Completed | Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A Hemophilia A | Phase 3 | 2019-01-21 |
| Unknown | Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or Lymp Advanced Solid Tumors or Lymphoma | Phase 1 | 2018-12-13 |
| Unknown | Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma Head and Neck Cancer | Phase 2 | 2018-11-28 |
| Unknown | Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumo Advanced Solid Tumors | Phase 1 | 2018-09-30 |
| Unknown | Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer Triple Negative Breast Neoplasms | Phase 2 | 2018-07-20 |
| Unknown | Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | 2018-07-17 |
| Unknown | Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC Metastatic Colorectal Cancer | Phase 2 | 2018-02-12 |
| Unknown | Efficacy and Safety Study of SCT800 for On-demand Treatment With in Patients With Hemophilia A Hemophilia A | Phase 3 | 2016-10-01 |
| Unknown | Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A Hemophilia A | Phase 1 | 2016-09-01 |
| Unknown | A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Predni Diffuse Large B Cell Lymphoma | Phase 3 | 2016-06-01 |
| Unknown | A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma B-cell Non Hodgkin's Lymphoma | Phase 2 | 2015-05-01 |
| Unknown | Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclona Metastatic Colorectal Cancer | Phase 1 | 2015-01-01 |
| Completed | Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patient B-cell Non Hodgkin's Lymphoma | Phase 1 | 2012-05-01 |